According to a newly published market research report by 24LifeSciences, global veterinary molecular diagnostic service market was valued at USD 1.45 billion in 2024 and is projected to reach USD 2.15 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period 2025–2032.

Veterinary Molecular Diagnostic Service refers to specialized diagnostic services that utilize molecular techniques to identify and detect diseases, pathogens, genetic abnormalities, and other health conditions in animals. These advanced diagnostics involve the analysis of DNA, RNA, proteins, and other biomolecules to provide highly accurate and specific information, enabling precise disease diagnosis, prevention strategies, and treatment plans for companion animals and livestock.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/14260/veterinary-molecular-diagnostic-service-market

Rising Prevalence of Zoonotic and Infectious Diseases Fuels Market Growth

The increasing global prevalence of zoonotic and infectious diseases, particularly among animal populations, remains the primary growth driver for the veterinary molecular diagnostic service market. The expanding number of veterinary clinics, diagnostic laboratories, and research institutions has significantly increased demand for reliable diagnostic solutions that can provide rapid and accurate results for early disease detection and management.

In addition, molecular diagnostics' proven role in detecting emerging pathogens and genetic disorders ensures steady and recurring demand from veterinary healthcare settings worldwide, supporting better animal health outcomes and reducing transmission risks to humans.

Technological Advancements Enhance Diagnostic Accuracy and Accessibility

Technological advancements in PCR, next-generation sequencing, and microarray technologies have transformed the market by improving diagnostic accuracy, sensitivity, and turnaround time, while reducing dependence on traditional culture-based methods. These innovations have strengthened regulatory acceptance and enabled diagnostic service providers to scale their operations efficiently, supporting long-term market expansion.

Ongoing research exploring novel diagnostic applications, including point-of-care testing and AI-powered analysis, is further opening new growth avenues for the veterinary molecular diagnostic service market.

Market Challenges: Cost Pressures and Regulatory Complexities

Despite positive growth trends, the market faces notable challenges:

• High equipment and reagent costs associated with molecular diagnostic technologies

• Stringent regulatory approval pathways for veterinary diagnostic tests in major markets

• Competition from traditional diagnostic methods such as culture-based tests and rapid antigen tests

• Shortage of skilled professionals with expertise in molecular techniques, particularly in developing regions

Additionally, limited awareness among veterinarians and pet owners about the benefits of molecular diagnostics has restricted market penetration in certain geographic areas.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/veterinary-molecular-diagnostic-service-market-14260

North America Leads the Global Veterinary Molecular Diagnostic Service Market

The North American region, led by the United States, dominates the global veterinary molecular diagnostic service market, accounting for approximately 42% of total market share. This leadership is driven by:

• Advanced veterinary healthcare infrastructure and high pet adoption rates

• Strong presence of major diagnostic service providers and research institutions

• Favorable regulatory frameworks for veterinary diagnostics

• Increasing pet insurance coverage and expenditure on animal health

Europe and Asia-Pacific remain important secondary markets, supported by growing awareness of animal health and increasing investments in veterinary healthcare infrastructure.

Veterinary Hospitals Segment Dominates Market by End User

By end user, veterinary hospitals represent the largest and most critical segment due to the comprehensive nature of diagnostic services requiring specialist supervision and advanced equipment.
By technology, PCR-based diagnostics holds the dominant share owing to its proven reliability, cost-effectiveness, and widespread adoption in veterinary diagnostic settings.

Competitive Landscape: Moderately Consolidated with Key Global Players

The global veterinary molecular diagnostic service market is moderately consolidated, with the top players collectively accounting for significant market share. The competitive environment is shaped by technological expertise, service quality, regulatory compliance, and geographic coverage.

Key companies profiled in the report include:

• IDEXX Laboratories

• BioMrieux

• VCA

• Bioneer

• Heska

• Zoetis

• Neogen

• and More

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/veterinary-molecular-diagnostic-service-market-14260

Market Opportunities: Emerging Economies and Point-of-Care Testing

Significant growth opportunities exist in emerging markets across Asia-Pacific and Latin America, supported by improving veterinary healthcare access and rising awareness of advanced diagnostic technologies. Furthermore, the development of point-of-care molecular diagnostic devices, including portable PCR systems and rapid testing platforms, is expected to generate new service models and expand clinical adoption in smaller veterinary practices.

Access the Full Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/14260/veterinary-molecular-diagnostic-service-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/veterinary-molecular-diagnostic-service-market-14260

About 24LifeSciences

24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.

Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/